HLS Therapeutics Inc is making waves on the TSX with a notable surge in stock price, closing up 7.38% in the last session.
In a remarkable turn of events, HLS Therapeutics Inc (HLS.TO) has seen its stock price jump by 7.38%, closing at CA$4.80. This surge comes amidst a backdrop of positive financial results and strategic moves that are garnering investor attention.
Investor takeaway: Today's impressive gain reflects growing confidence in HLS Therapeutics, particularly following its recent financial performance and product launches.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$128.85M
52W high
$5.76
52W low
$4.00
1W change
-3.06%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 76.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.26
+76.2% Upside
Current Price
C$4.12
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
27.8%
Annualized
90-Day Vol
22.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.45
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.88 | C$3.53 – C$4.27 |
| 60 trading days | C$3.66 | C$3.19 – C$4.19 |
| 90 trading days | C$3.45 | C$2.92 – C$4.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
HLS Therapeutics Inc sees a 7.38% stock price increase in one day.
The stock's closing price of CA$4.80 reflects a growing optimism among investors, with analysts projecting a price target of CA$7.25, indicating a potential upside of approximately 65%.
Bull case
The company reported a 2% year-over-year revenue increase in Q1 2026, along with a 15% growth in Vascepa net sales. This shows a strong market position and suggests potential for future revenue growth.
Bear case
Despite the positive momentum, HLS Therapeutics is still operating at a loss, with a profit margin of -0.1846. This could raise concerns for more cautious investors.
Financial Performance Boosts Investor Confidence
Advertisement
HLS Therapeutics recently reported Q1 2026 revenue of CA$12.9 million, marking a 2% increase year-over-year. This growth, especially in Vascepa net sales, has helped boost investor confidence, contributing to the stock's impressive rise.
Strategic Product Launches Enhance Market Position
The upcoming commercial launch of NILEMDO™ in April 2026, along with its recent approval by Health Canada, positions HLS Therapeutics to capture a larger share of the market. This strategic move is expected to drive further revenue growth and solidify its standing in the pharmaceutical industry.
Analysts Weigh In: Future Outlook
Analysts have set a price target of CA$7.25 for HLS Therapeutics, indicating a potential upside of approximately 65%. This optimistic outlook is based on the company's recent financial results and successful product launches, making it an attractive option for investors looking for growth in the healthcare sector.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
